49th week of 2013 patent applcation highlights part 59 |
Patent application number | Title | Published |
20130324475 | Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation - A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents. | 2013-12-05 |
20130324476 | COSMETIC USE OF DERMICIDIN, AND ANALOGUES OR FRAGMENTS THEREOF - The present invention relates, in particular, to the use of a sequence of amino acids of dermicidin or an analogue or fragment thereof, and at least one sequence of nucleic acids coding said sequence as a biomarker for ageing skin and/or the signs of skin ageing which are possibly associated with skin dryness. | 2013-12-05 |
20130324477 | PEPTIDES THAT MODULATE COMPLEX SASPASE-FLG2 - The invention relates to a peptide isolated from SASpase or FLG2, a fragment or homologue thereof, which can modify the three-dimensional shape of a complex formed by interaction between a first amino acide sequence from Filaggrin-2 and a second amino acid sequence from SASPase. | 2013-12-05 |
20130324478 | Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration - The present invention relates to the field of medicine and biology. It concerns a new test for screening and therapeutic follow-up in oncology. More particularly, it relates to diagnostic and/or therapeutic tests in oncology and on neurodegenerative diseases. Molecular targeting by peptide vectors and antibodies or by small interfering RNAs (siRNAs) opens a new concept of interdependence for diagnostic and therapeutic tools. | 2013-12-05 |
20130324479 | METHODS FOR INDUCING EPITHELIAL CANCER CELL SENESCENCE - Systems, methods, and computer readable media for diagnosing or characterizing epithelial cancer or its stages based on the level of expression of the Wnt5a gene or protein are provided. The level of nucleic acids encoding Wnt5a or the level of Wnt5a protein is measured in a tissue sample, and the level is compared with reference values. Methods for inducing senescence of an epithelial cancer cell are also provided. | 2013-12-05 |
20130324480 | CYCLOSPORIN A ANALOGS - The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye. | 2013-12-05 |
20130324481 | SUSTAINED RELEASE EYE DROP FORMULATIONS - This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably α-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents. | 2013-12-05 |
20130324482 | COMPSTATIN ANALOGS FOR TREATMENT OF RHINOSINUSITIS AND NASAL POLYPOSIS - In some aspects, the present invention provides methods treating a subject in need of treatment for chronic rhinosinusitis or nasal polyposis, the methods comprising administering a complement inhibitor such as a compstatin analog to the subject. In some embodiments, the complement inhibitor is administered intranasally, e.g., in a nasal spray. | 2013-12-05 |
20130324483 | MAMMALIAN CELL SURFACE ANTIGENS; RELATED REAGENTS - Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided. | 2013-12-05 |
20130324484 | LIVER FUNCTION-IMPROVING AGENT - The present invention provides a liver function-improving agent or an inhibitor of fat accumulation in the liver, which contains maltitol as an active ingredient. The present invention also provides a medicament for the prevention and/or treatment of hepatic dysfunction, which contains maltitol as an active ingredient. | 2013-12-05 |
20130324485 | Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy with Cardiac Glycoside - A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside. | 2013-12-05 |
20130324486 | METHOD FOR PRODUCING CULTURED ROOT OF PURPLE GINSENG - The present invention relates to a novel method for processing a cultured root of purple wild ginseng for increasing saponin content and to the cultured root of the purple wild ginseng which is processed thereby. The present invention can provide the cultured root of wild ginseng having significantly higher content of a specific ginsenoside, and can increase the productivity and economic efficiency by simplifying the production process. | 2013-12-05 |
20130324487 | Cyanidin-3-glucoside and Methods for Using the Same - The present invention provides diet supplement compositions comprising cyanidin-3-glucoside (C3G) or C3G source or extracts and methods for using the same to aid in bodily fat loss. | 2013-12-05 |
20130324488 | NEW ANTIFUNGAL COMPOSITIONS - The present invention relates to new antifungal compositions and their use in the treatment of agricultural products. | 2013-12-05 |
20130324489 | NEW ANTIFUNGAL COMPOSITIONS - The present invention relates to new antifungal compositions and their use in the treatment of agricultural products. | 2013-12-05 |
20130324490 | BIODEGRADABLE, WATER SOLUBLE AND PH RESPONSIVE POLY(ORGANO)PHOSPHAZENES - The present invention relates in general to the field of targeted drug delivery of anti-cancer drugs. More precisely, the present invention concerns polymer drug conjugates, namely, conjugates of poly(organo)phosphazenes and anti-cancer drugs, wherein the conjugates are suitable to selectively release anti-cancer drugs in tumor tissue. In addition, the present invention relates to a method for manufacturing such poly(organo)phosphazene molecule conjugates, to poly(organo)phosphazene molecule conjugates for use in medicine, in particular, to poly(organo)phosphazene molecule conjugates for use in the treatment of cancer, and to pharmaceutical compositions comprising such poly(organo)phosphazene molecule conjugates. | 2013-12-05 |
20130324491 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B - This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: | 2013-12-05 |
20130324492 | Maintenance of Platelet Inhibition During Antiplatelet Therapy - A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis. The method can further be used in patients who were previously treated with long-acting platelet inhibitors without increasing the risk of excessive bleeding. | 2013-12-05 |
20130324493 | COMPOSITIONS COMPRISING NINGNANMYCIN AND USES THEREFOR - Provided herein are compositions comprising ningnanmycin or a derivative thereof, as well as their use for controlling or combating a fungal infection in a plant or plant part (e.g., a turfgrass). | 2013-12-05 |
20130324494 | NOVEL PHARMACEUTICAL COMPOUNDS - Novel compounds and pharmaceutical compositions are provided. In one aspect of the invention the compounds may be utilized in medical practice, for example, in treatment of cancer and immune disorders. | 2013-12-05 |
20130324495 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF - The invention provides particular uridine di- and tri-phosphate derivatives, and pharmaceutical compositions thereof. These compounds are useful for treatment of diseases, disorders and conditions modulated by P2Y6 receptors, and particularly for lowering intraocular pressure and thereby treating ocular hypertension and/or glaucoma. | 2013-12-05 |
20130324496 | SOLID FORMS OF AN ANTIVIRAL COMPOUND - Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: | 2013-12-05 |
20130324497 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION - The invention generally relates to compositions and methods for treating hepatitis B virus infection. More particularly, the invention relates to treating hepatitis B virus infection and related conditions in humans using unique and synergistic combinations of lamivudine and adefovir that maximize favorable therapeutic outcomes while minimizing or preventing viral resistance, which commonly occurs from using lamivudine or adefovir alone, and reducing the side effects of adefovir. | 2013-12-05 |
20130324498 | Crystalline Forms of Tenofovir Dipivoxil Fumarate - The present invention relates to a crystalline form of tenofovir dipivoxil fumarate, a crystalline composition and a pharmaceutical composition comprising the crystalline form, and also to a process for preparing the same and the use for prophylaxis or treatment of a disease associated with a viral infection. The crystalline form has an X-ray powder diffraction pattern using Cu-Kα radiation, expressed in terms of lattice spacing “d” comprising peaks at about 18.4714 Å, 5.0350 Å, 4.6380 Å, 4.5347 Å, 4.3838 Å, 4.2874 Å and 3.6304 Å. | 2013-12-05 |
20130324499 | MOISTURISER BLEND - A blend for use in a personal care composition comprises a dialkyl amphiphilic component and an ester of a long chain branched fatty acid and a long chain branched alcohol. The blend can be pastillated and/or flaked, and can be used as the oil phase of an oil-in-water emulsion. The blend can be used in a moisturiser composition for moisturising skin. | 2013-12-05 |
20130324500 | SPINAL CORD INJURY, INFLAMMATION AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS - A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury. | 2013-12-05 |
20130324501 | DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS - Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols according to formula (I) are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. | 2013-12-05 |
20130324502 | NOVEL FORMULATIONS FOR DERMAL, TRANSDERMAL AND MUCOSAL USE 1 - A dermal, transdermal and/or mucosal formulation for topical application on skin, comprising an active pharmaceutical ingredient and a pharmaceutically acceptable solvent, and an anti-solvent; wherein the active pharmaceutical ingredient is soluble in the solvent in the absence of the anti-solvent, and wherein the active pharmaceutical ingredient is substantially in the solid state in the presence of the anti-solvent. A method for increasing the stability of an active pharmaceutical ingredient. | 2013-12-05 |
20130324503 | Method of identifying and treating a person having a predisposition to or afflicted with Parkinson disease - The present invention relates to methods of treatment for Parkinson Disease (PD) in a person by identifying gene variants which may indicate a more favorable response to specific medicaments, thereby allowing for personalized or individualized treatment. The present invention relates to a method of screening for a genetic predisposition to PD in a person. The present invention is also directed to a method of testing a person for the presence of particular gene variants, wherein the presence of a gene variant indicates a higher predisposition to PD, and the absence of a gene variant indicates a lower predisposition to PD, compared to a control sample. The present invention further relates to methods and kits for treating, or inhibiting the development of, PD in a person. The present invention is also directed to a method of identifying the heritage of an individual based on the genetic profile of the individual. | 2013-12-05 |
20130324504 | ANTISPASMODIC 1,2-DIOLS AND 1,2,3-TRIOLS - The present invention is directed to pharmaceutical compositions comprising antispasmodic C | 2013-12-05 |
20130324505 | ASSAYS AND METHODS OF TREATMENT RELATING TO VITAMIN D INSUFFICIENCY - Described herein are assays directed to determining the level of bioavailable or free vitamin D in a blood sample in a subject. The values determined for bioavailable or free vitamin D indicate whether the subject suffers from insufficient levels of vitamin D. Also described herein are methods of treatment for vitamin D insufficiency. | 2013-12-05 |
20130324506 | New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands - The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use. | 2013-12-05 |
20130324507 | Novel (aza)Benzhydryl Ether Derivatives, Their Process of Preparation and Their Use as H4-Receptor Ligands for Therapeutical Applications - The present invention concerns novel (aza)benzhydryl ether derivatives which exhibit H4-receptor binding activity. The present invention also concerns their process of preparation and their therapeutical uses. | 2013-12-05 |
20130324508 | BIOMARKER FOR PROSTATE CANCER AND METHOD OF USING THE SAME - The present invention relates to a biomarker for characterizing prostate cancer and method of using the same. More particularly, the invention relates to method of using a membrane-associated C family G protein-coupled receptor GPRC6A as biomarker of characterizing prostate cancer progression. The present invention also provides a kit for detecting prostate cancer in a subject. | 2013-12-05 |
20130324509 | SPINAL CORD INJURY, INFLAMMATION, AND IMMUNE-DISEASE: LOCAL CONTROLLED RELEASE OF THERAPEUTIC AGENTS - A drug delivery system is provided for treatment of oxidative stress. The drug delivery system can include a therapeutic agent and a matrix. The therapeutic agent can include an antioxidant or steroid. The matrix can include a hydrogel, particle, microparticle, or nanoparticle. A method of treating injury, including peripheral nerve injury or spinal cord injury, is also provided. The method includes injecting the drug delivery system at the site of injury. | 2013-12-05 |
20130324510 | DELIVERY OF HYDROPHOBIC BIOACTIVE AGENTS - A composition for delivery of a hydrophobic bioactive agent is provided that provides for a partially solubilized storage solution that upon exposure to the air results in a fully solubilized bioactive agent in a molecular form for optimal delivery to the skin of a subject. The composition is used for the therapeutic treatment or diagnosis of numerous skin conditions such as acne, wrinkles, inflammation, and epidermal or musculoskeletal pain. | 2013-12-05 |
20130324511 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLOMETALATED N-HETEROCYCLIC CARBENE COMPLEXES FOR CANCER TREATMENT - The present disclosure is related to a pharmaceutical composition for treatment of cancer comprising a cyclometalated N-heterocyclic carbene complex. The cyclometalated N-heterocyclic carbene complex contains a gold(III) or a platinum(II) atom. The pharmaceutical composition possesses anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of topoisomerase and/or poisoning of topoisomerase. | 2013-12-05 |
20130324512 | SUPER-OXIDE DISMUTASE MIMETICS - The present invention relates to compounds which are effective as catalysts for dismutating superoxide and, more particularly, the manganese or iron complexes of substituted, unsaturated heterocyclic 16-membered macrocyclic complexes that catalytically dismutate superoxide. It also relates to methods of using these complexes to reduce the concentration or the effects of superoxide, pharmaceutical compositions comprising these compounds or their metal complexes, and methods of treating conditions associated with excessive superoxide activity. | 2013-12-05 |
20130324513 | METHOD FOR TREATING ESOPHAGEAL CANCER - Methods and compositions for treating gastric and esophageal cancers are disclosed. | 2013-12-05 |
20130324514 | INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS - The present invention relates to compounds of general formula I, | 2013-12-05 |
20130324515 | IMIDAZOTRIAZINES AND IMIDAZOPYRIMIDINES AS KINASE INHIBITORS - The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. | 2013-12-05 |
20130324516 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES - The invention provides novel compounds having the general formula: | 2013-12-05 |
20130324517 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD - The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. | 2013-12-05 |
20130324518 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME - Provided are 4′-arylmethoxy isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed. | 2013-12-05 |
20130324519 | QUINOXALINE CARBOXAMIDE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS - The invention relates to compounds of formula (I) | 2013-12-05 |
20130324520 | RXRG MODULATORS FOR THE TREATMENT OF CANCER - The present invention provides methods for treating cancer using modulators of retinoid X receptor gamma (RXRG). The ability of RXRG antagonists to disrupt the association of complexes comprising RXRG is demonstrated. | 2013-12-05 |
20130324521 | IMPLANT FOR TREATING OR PREVENTING AN ANEURYSM - A medical product ( | 2013-12-05 |
20130324522 | INSECT ODORANT RECEPTOR ANTAGONISTS - Insect repellent compositions are disclosed which are antagonists of insect odorant receptors. These compositions are useful as insect repellents and confusants. These insect repellent compositions may be suitable for topical application. Also disclosed are methods for interfering with the ability of an insect to detect odors. This is accomplished by exposing an insect to an olfactory-disrupting concentration of a compound. | 2013-12-05 |
20130324523 | TAU IMAGING PROBE - An object of the present invention is to provide a probe for imaging a β-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. | 2013-12-05 |
20130324524 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES - The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades. | 2013-12-05 |
20130324525 | SUBSTITUTED HETEROCYCLIC COMPOUNDS - The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): | 2013-12-05 |
20130324526 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINE COMPOUNDS AS INHIBITORS OF THE C-MET TYROSINE KINASE - The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I). | 2013-12-05 |
20130324527 | IMIDAZOPYRIDINES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS - A compound satisfying formula I, a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof: | 2013-12-05 |
20130324528 | PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 - The present invention provides ALK5 inhibitors of the formula | 2013-12-05 |
20130324529 | BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP - The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans. | 2013-12-05 |
20130324530 | 3-(AMINOARYL)-PYRIDINE COMPOUNDS - The present invention provides a compound of formula (I): | 2013-12-05 |
20130324531 | SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES - There are provided compounds of the formula | 2013-12-05 |
20130324532 | FAK INHIBITORS - A compound of the formula (I): | 2013-12-05 |
20130324533 | METHOD OF DETECTING RESISTANCE TO CANCER THERAPY - We describe a polymorphic variant of a BIM {BCL2L11) gene which comprises, in 5′ to 3′ order, the nucleotide sequence set out in SEQ ID NO: 5 followed immediately by the nucleotide sequence set out in SEQ ID NO: 7. The BIM polymorphic variant may be characterised by lacking the nucleotide sequence set out in SEQ ID NO: 6. It may be used to detect BCR-ABL-independent TKI-resistance (resistance to treatment with tyrosine kinase inhibitors) for chronic myelogenous leukaemia, c-KIT/PDGFR-independent TKI-resistance for gastrointestinal stromal tumours (GIST), EGFR-independent TKI-resistance for non-small cell lung cancer (NSCLC) or JAK2-independent TKI-resistance for a myeloproliferative disorder, in an individual comprising such a polymorphism. | 2013-12-05 |
20130324534 | COMBINATION OF BRIMONIDINE AND TIMOLOL FOR TOPICAL OPHTHALMIC USE - Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans. | 2013-12-05 |
20130324535 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN - The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to bone cancer. | 2013-12-05 |
20130324536 | PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF - The invention provides pyrazolyl guanidine compounds that inhibit F | 2013-12-05 |
20130324537 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS - The present invention relates to guanidine compounds of the general formula I | 2013-12-05 |
20130324538 | ISOXAZOLINE DERIVATIVES FOR CONTROLLING INVERTEBRATE PESTS - The invention relates to new isoxazoline compounds of formula | 2013-12-05 |
20130324539 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate - Improved methods of treating multiple sclerosis and/or psoriasis using prodrugs of methyl hydrogen fumarate are disclosed. The methods comprise administering certain prodrugs of methyl hydrogen fumarate. The methods are able to achieve high blood plasma concentrations of the active metabolite, methyl hydrogen fumarate, without causing significant gastrointestinal irritation. New prodrugs of methyl hydrogen fumarate are also disclosed. | 2013-12-05 |
20130324540 | USE OF GLUTARIC ACID DERIVATIVES OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS ANTI-ARRHYTHMIC AGENTS - The invention relates to the use of glutaric acid derivatives of general formula (I), which are disclosed in the invention description, as anti-arrhythmic agents. | 2013-12-05 |
20130324541 | POTENTIATOR OF ANTITUMOR ACTIVITY OF CHEMOTHERAPEUTIC AGENT - The present invention relates to an agent for potentiating an antitumor activity of a chemotherapeutic agent against a cancer containing cancer stem cells, which contains at least one kind of branched chain amino acid selected from isoleucine, leucine and valine, or a salt thereof. In addition, the present invention relates to an agent for treating a cancer containing cancer stem cells, which contains a combination of a chemotherapeutic agent and at least one kind of branched chain amino acid selected from isoleucine, leucine and valine, or a salt thereof. Furthermore, the present invention relates to an agent for preventing metastasis or recurrence of a cancer containing cancer stem cells, which contains a combination of a chemotherapeutic agent and at least one kind of branched chain amino acid selected from isoleucine, leucine and valine, or a salt thereof. | 2013-12-05 |
20130324542 | [1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF - The present invention relates to a structurally novel [1,2,4]triazolo[4,3-b][1,2,4]triazine compounds represented by formula (I) or formula (II), pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates or solvates thereof, and also relates to a preparation method of the compounds, a pharmaceutical composition including a therapeutically effective amount of the compounds, as well as the use thereof as protein tyrosine kinase inhibitors, particularly as c-Met inhibitors, in the preparation of medicaments for the prevention and/or treatment of diseases associated with c-Met abnormality. | 2013-12-05 |
20130324543 | REVERSAL OF HIGH BREAST CANCER RISK IN MAMMALS EXPOSED TO ESTROGENIC CHEMICALS IN UTERO BY ADULT EXPOSURE TO HDAC AND DNMT INHIBITORS - Methods of reducing breast cancer risk in an individual exposed in utero to an elevated estrogenic environment, where the individuals are identified by obtaining a measurement of at least one of: (a) DNMT1 expression; (b) methylation of normally unmethylated CpG islands of tumor suppressor genes; and (c) polycomb target genes, in cells obtained from the individual and comparing the measurement to a statistical level of a population not exposed in utero to an elevated estrogenic environment. Methods of reducing breast cancer risk in such an individual can be reduced by administering at least one DNA methyltransferase (DNMT) and/or histone deacetylase (HDAC) inhibitor. The administration of these inhibitors may be part of a treatment regime which may include the administration of at least one anti-cancer agent. | 2013-12-05 |
20130324544 | MICROBICIDAL HETEROCYCLES - Compounds of the formula I Formula (I) wherein the substituents are as defined in claim | 2013-12-05 |
20130324545 | METHODS FOR THE REGULATION OF THE PROSTAGLANDIN F SYNTHASE (PGFS) ACTIVITY OF AKR1B1 AND USES THEREOF - AKR1B1 (EC 1.1.1.21) is an aldose reductase that has mainly been associated with the polyol pathway, and more recently with lipid deperoxidation. We have discovered that the primary activity of this enzyme is rather a PGFS activity, catalyzing the transformation of PGH | 2013-12-05 |
20130324546 | SELECTIVE FAK INHIBITORS - A compound of the formula (I): | 2013-12-05 |
20130324547 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS - Embodiments of the disclosure relate to tetrahydropyrazolopyrimidine compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis | 2013-12-05 |
20130324548 | CHEMOEMBOLIZATION COMPOSITION COMPRISING ANTI-ANGIOGENIC AGENTS - The invention relates to chemoembolization composition for anti-angiogenic agent delivery. The invention further relates to a method of preparing chemoembolization composition and to the use of chemoembolization composition in the method for treating solid tumour cancers. | 2013-12-05 |
20130324549 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure. | 2013-12-05 |
20130324550 | 1-(2-PHENOXYMETHYLHETEROARYL) PIPERIDINE AND PIPERAZINE COMPOUNDS - The invention relates to compounds of formula I: | 2013-12-05 |
20130324551 | THIAZOLYLPHENYL-BENZENESULFONAMIDO DERIVATIVES AS KINASE INHIBITORS - Thiazolylphenyl-benzenesulfonamido derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 2013-12-05 |
20130324552 | CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USED RELATED THERETO - The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer. | 2013-12-05 |
20130324553 | MICROBIOCIDAL PYRAZOLE DERIVATIVES - The present invention provides compounds of formula (I): wherein the substituents are as defined in claim | 2013-12-05 |
20130324554 | AMORPHOUS FORM OF VILAZODONE HYDROCHLORIDE SUBSTANTIALLY FREE OF CRYSTALLINE FORMS - Disclosed herein is a stable amorphous form of vilazodone hydrochloride substantially free of crystalline forms, a process for the preparation, pharmaceutical compositions, and methods of treating thereof. Disclosed also herein are stable amorphous co-precipitates of vilazodone hydrochloride and a pharmaceutically acceptable excipient, methods for the preparation, pharmaceutical compositions, and method of treating thereof. | 2013-12-05 |
20130324555 | Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals - The present invention is directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a salicylanilide or salicylanilide derivative, disclosed herein, alone or in combination with one or more other active or excipient pharmaceutical substances. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein, further comprised of one or more active or excipient pharmaceutical substances. | 2013-12-05 |
20130324556 | Protease Activated Receptor 2 (PAR2) Antagonists - A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrate thereof | 2013-12-05 |
20130324557 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 - The present invention includes compounds useful as modulators of TRPM8, such as compounds of Formula (I) and the subgenus and species thereof; personal products containing those compounds; and the use of those compounds and the personal products, particularly the use of increasing or inducing chemesthetic sensations, such as cooling or cold sensations. | 2013-12-05 |
20130324558 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE - The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-β) inhibitors, and to methods for regulating angiogenesis. | 2013-12-05 |
20130324559 | DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES - Sodium channel blockers represented by the formula: | 2013-12-05 |
20130324560 | ANTHRANILIC ACID DIAMIDE DERIVATIVE WITH HETERO-AROMATIC AND HETERO-CYCLIC SUBSTITUENTS - The present invention relates to new insecticides of the formula (I) | 2013-12-05 |
20130324561 | ATROPISOMERS OF P13K-INHIBITING COMPOUNDS - The invention provides compounds, compositions and methods to treat certain inflammatory conditions or cancers by administering a compound that inhibits PI3K isoforms, wherein the compounds are optically active atropisomers. It provides optically active stereoisomers of a class of pyrazole-containing compounds, which are useful for these methods, and provides methods to obtain these compounds as well as pharmaceutical compositions containing these compounds. | 2013-12-05 |
20130324562 | FUSED BICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS - The present invention is directed to novel bicyclic heterocycles of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2013-12-05 |
20130324563 | METHOD OF INTENSIFYING THE PHYSIOLOGICAL ACTION OF CAFFEINE - It is an object of the present invention to provide: a method for safely and effectively enhancing the physiological action of caffeine even from a low intake of caffeine, when utilized various types of a physiological action of a caffeine which involve stimulation of the central nerve to promote mental function; and a composition for improving physiological function, which comprises, as an active ingredient, the caffeine whose physiological action has been enhanced. As a means to solve the above-mentioned object, the physiological action of caffeine is enhanced by combining caffeine with ornithine or a salt thereof. In addition, the ornithine or a salt thereof in an amount equivalent to 0.1 to 100 parts by weight of free ornithine based on 1 part by weight of the caffeine is mixed with caffeine, as an agent for enhancing the physiological action of caffeine, thereby providing a composition for improving a physiological function comprising caffeine as an active ingredient. The improvement of a physiological function by caffeine in the present invention is the improvement of a physiological function by mental fatigue-reducing action, drowsiness-preventing action, or concentration-maintaining action. | 2013-12-05 |
20130324564 | POLYMORPHS OF (S)-1-(4,4,6,6,6-PENTADEUTERO-5-HYDROXYHEXYL)-3-7-DIMETHYL-1H-PURINE-2,6(- 3H,7H)-DIONE - The present invention provides individual crystalline polymorphs of (S)-1-(4,4,6, 6,6-pentadeutero-5-hydroxy-hexyl)-3,7-dimethyl-1H-purine-2,6(3H,7H)-dione designated Form 1, Form 2, Form 3 and Form 4. Each polymorph disclosed herein is characterized according to one or more of (a) powder X-ray diffraction data (“XRPD”); (b) differential scanning calorimetry (“DSC”); and (e) thermo gravimetric analysis (TGA). | 2013-12-05 |
20130324565 | ORGANIC COMPOUNDS - The present invention relates to optionally substituted (5- or 7-oxy)-3,4-dihydro-(optionally 4-oxo, 4-thioxo or 4-imino)-1H-pyrrolo[3,4-d]pyrimidin-2(3H,6H)-ones, e.g., Compounds of Formula II-A′ or II-B′ as described herein, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them. | 2013-12-05 |
20130324566 | PYRIMIDINE COMPOUNDS INHIBITING THE FORMATION OF NITRIC OXIDE AND PROSTAGLANDIN E2, METHOD OF PRODUCTION THEREOF AND USE THEREOF - The invention provides pyrimidine compounds of general formula (I), which reduce simultaneously the production of nitric oxide (NO) and prostaglandin E2 (PGE2). They have no negative effect on the viability of cells in concentrations decreasing the production of these factors by up to 50%; they are not cytotoxic. Furthermore, a method of preparation of the pyrimidine compounds of general formula (I), carrying 2-formamido group, a pharmaceutical composition comprising the substituted pyrimidine compounds according to the invention, and the use of these compounds for the treatment of inflammatory and cancer diseases are provided. | 2013-12-05 |
20130324567 | RESTORATION OF HAIR - A nonirritant composition which is useful in restoring hair and which comprises a normally solid, water-insoluble hair restorer, for example, minoxidil, a normally solid Hsieh dermal penetration-facilitator for the hair restorer, for example, pentadecalactone, and a solvent or co-solvent in which the hair restorer and the facilitator are solubilized and which does not impart to the composition irritant properties, and wherein, upon application to the surface of the skin of a recipient, the hair restorer penetrates the dermal layer of the skin and with minimal systemic delivery of the hair restorer into the blood stream of the recipient. | 2013-12-05 |
20130324568 | SUBSTITUTED INDOLYL ALKYL AMINO DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE - This invention comprises the novel compounds of formula (I) | 2013-12-05 |
20130324569 | PEGYLATED CYCLOPAMINE ANALOGUE, PREPARATION METHOD AND USES THEREOF - A PEGylated cyclopamine analog, preparation method, uses thereof and methods for treating proliferative diseases using the same are disclosed. The PEGylated cyclopamine analog is a compound represented by the following formula I, a compound comprising at least one group represented by the following formula I (in formula I, R is straight or branched polyethylene glycol having a molecular weight between 200 and 200,000 Dalton, L and X are linking groups), or their single enantiomers, mixture of enantiomers, mixture of diastereomers, pharmaceutically acceptable salts, solvates, or hydrates. | 2013-12-05 |
20130324570 | INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS - The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formulas (I)-(XXVI) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC. | 2013-12-05 |
20130324571 | N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS - The present invention relates to novel N-(imidazolidin-2-ylidene)-heterocyclo penta[b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. | 2013-12-05 |
20130324572 | REMEDY FOR PSYCHONEUROTIC DISEASES - A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient. | 2013-12-05 |
20130324573 | SUBSTITUTED 1, 2, 3, 4-TETRAHYDROQUINOLIN-7-YL CARBAMATES AS ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE - The present invention relates to novel substituted 1,2,3,4-tetrahydroquinolin-7-yl carbamates, their preparation, and use as therapeutic agents, particularly in the prevention or treatment of neurodegenerative or Alzheimer's disease, or senile dementia, or memory disturbances, and more particularly to the prevention, treatment and amelioration of Alzheimer's disease with the novel substituted 1,2,3,4-tetrahydroquinolin-7-yl carbamates, which act as inhibitors of central cholinesterase enzymes, particularly acetylcholinesterase (AChE) following the indirect cholinomimetic pathway. The present invention particularly relates to compounds of formula A: Formula A wherein R | 2013-12-05 |
20130324574 | TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD - Disclosed is a method for treating an ocular inflammatory disease (OID), e.g., uveitis or conjunctivitis, comprising periodic administration of a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating a subject suffering from an OID, uveitis, bacterial conjunctivitis, viral conjunctivitis, an inflammation of the orbital tissue, the lacrimal apparatus, the eyelid, the cornea, the retina or the optic pathway. This application also provides a method for treating a subject suffering from an autoimmune disease-associated ocular inflammation comprising periodic ocular administration to the subject a therapeutically effective amount of laquinimod or a pharmaceutically acceptable salt, and an ocular pharmaceutical composition comprising laquinimod or a pharmaceutically acceptable salt thereof for use in treating an autoimmune disease-associated ocular inflammation. | 2013-12-05 |